UNSPSC 51384802: Etoricoxib

This classification denotes a cyclooxygenase inhibitor with the molecular formula C18H15ClN2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WRX4NFY03R, chemically known as 2,3-bipyridine, 5-chloro-6-methyl-3-(4-(methylsulfonyl)phenyl)- but generally known as etoricoxib, which bears US NIH Compound Identifier 123619. European Medicines Agency schedules Etoricoxib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16429MIG.

UNSPSC 51384802 Etoricoxib, a Commodity code, nominally covers a single nonsteroidal anti-inflammatory drug product. Recent state and local solicitations tagged to this code, however, show no actual procurement of etoricoxib; instead, they reflect broader pharmaceutical supply and community health initiatives that fall outside the code's specific drug scope. Seminole County, Florida solicited naloxone and drug deactivation systems through an IFB, and the Texas Health and Human Services Commission issued an RFI on direct-to-manufacturer prescription programs. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP for generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesalers. None of these opportunities target etoricoxib as a line item or procurement focus. The code shows little relevant recent activity aligned with its nominal pharmaceutical scope; the opportunities currently tagged to it do not represent purchases of the specific drug product the code names.

The geographic spread reflects disparate state and local jurisdictions—Florida, Texas, and Minnesota—with MMCAP's cooperative vehicle extending to Oregon as well. The Seminole County IFB (solicitation IFB60459723LAS, due July 26, 2023) sought annual naloxone and drug deactivation systems on a quarterly delivery schedule. The Texas RFI (HHS0017013, posted April 3, 2026) explored vendor capacity for direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager channels. The MMCAP RFP (S1070000015802, due March 26, 2026) established multiple-award contracts for generic pharmaceuticals and OTC products through three authorized wholesalers, with evaluation weighted 75 percent on price competitiveness and effective July 1, 2026. Business development professionals should not expect current procurement activity under UNSPSC 51384802 for etoricoxib specifically; the code's tagging does not reflect the actual work state and local buyers are conducting right now.